These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 23829549)

  • 1. The discovery of PLK4 inhibitors: (E)-3-((1H-Indazol-6-yl)methylene)indolin-2-ones as novel antiproliferative agents.
    Laufer R; Forrest B; Li SW; Liu Y; Sampson P; Edwards L; Lang Y; Awrey DE; Mao G; Plotnikova O; Leung G; Hodgson R; Beletskaya I; Mason JM; Luo X; Wei X; Yao Y; Feher M; Ban F; Kiarash R; Green E; Mak TW; Pan G; Pauls HW
    J Med Chem; 2013 Aug; 56(15):6069-87. PubMed ID: 23829549
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The discovery of Polo-like kinase 4 inhibitors: identification of (1R,2S).2-(3-((E).4-(((cis).2,6-dimethylmorpholino)methyl)styryl). 1H.indazol-6-yl)-5'-methoxyspiro[cyclopropane-1,3'-indolin]-2'-one (CFI-400945) as a potent, orally active antitumor agent.
    Sampson PB; Liu Y; Forrest B; Cumming G; Li SW; Patel NK; Edwards L; Laufer R; Feher M; Ban F; Awrey DE; Mao G; Plotnikova O; Hodgson R; Beletskaya I; Mason JM; Luo X; Nadeem V; Wei X; Kiarash R; Madeira B; Huang P; Mak TW; Pan G; Pauls HW
    J Med Chem; 2015 Jan; 58(1):147-69. PubMed ID: 25723005
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The discovery of Polo-like kinase 4 inhibitors: design and optimization of spiro[cyclopropane-1,3'[3H]indol]-2'(1'H).ones as orally bioavailable antitumor agents.
    Sampson PB; Liu Y; Patel NK; Feher M; Forrest B; Li SW; Edwards L; Laufer R; Lang Y; Ban F; Awrey DE; Mao G; Plotnikova O; Leung G; Hodgson R; Mason JM; Wei X; Kiarash R; Green E; Qiu W; Chirgadze NY; Mak TW; Pan G; Pauls HW
    J Med Chem; 2015 Jan; 58(1):130-46. PubMed ID: 24867403
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design and optimization of (3-aryl-1H-indazol-6-yl)spiro[cyclopropane-1,3'-indolin]-2'-ones as potent PLK4 inhibitors with oral antitumor efficacy.
    Li SW; Liu Y; Sampson PB; Patel NK; Forrest BT; Edwards L; Laufer R; Feher M; Ban F; Awrey DE; Hodgson R; Beletskaya I; Mao G; Mason JM; Wei X; Luo X; Kiarash R; Green E; Mak TW; Pan G; Pauls HW
    Bioorg Med Chem Lett; 2016 Oct; 26(19):4625-4630. PubMed ID: 27592744
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structure-based design of potent and selective 3-phosphoinositide-dependent kinase-1 (PDK1) inhibitors.
    Medina JR; Becker CJ; Blackledge CW; Duquenne C; Feng Y; Grant SW; Heerding D; Li WH; Miller WH; Romeril SP; Scherzer D; Shu A; Bobko MA; Chadderton AR; Dumble M; Gardiner CM; Gilbert S; Liu Q; Rabindran SK; Sudakin V; Xiang H; Brady PG; Campobasso N; Ward P; Axten JM
    J Med Chem; 2011 Mar; 54(6):1871-95. PubMed ID: 21341675
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Thieno[3,2-c]pyrazoles: a novel class of Aurora inhibitors with favorable antitumor activity.
    Bindi S; Fancelli D; Alli C; Berta D; Bertrand JA; Cameron AD; Cappella P; Carpinelli P; Cervi G; Croci V; D'Anello M; Forte B; Giorgini ML; Marsiglio A; Moll J; Pesenti E; Pittalà V; Pulici M; Riccardi-Sirtori F; Roletto F; Soncini C; Storici P; Varasi M; Volpi D; Zugnoni P; Vianello P
    Bioorg Med Chem; 2010 Oct; 18(19):7113-20. PubMed ID: 20817473
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of pyrrole-indoline-2-ones as Aurora kinase inhibitors with a different inhibition profile.
    Chiang CC; Lin YH; Lin SF; Lai CL; Liu C; Wei WY; Yang SC; Wang RW; Teng LW; Chuang SH; Chang JM; Yuan TT; Lee YS; Chen P; Chi WK; Yang JY; Huang HJ; Liao CB; Huang JJ
    J Med Chem; 2010 Aug; 53(16):5929-41. PubMed ID: 20681538
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Functional characterization of CFI-400945, a Polo-like kinase 4 inhibitor, as a potential anticancer agent.
    Mason JM; Lin DC; Wei X; Che Y; Yao Y; Kiarash R; Cescon DW; Fletcher GC; Awrey DE; Bray MR; Pan G; Mak TW
    Cancer Cell; 2014 Aug; 26(2):163-76. PubMed ID: 25043604
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quinols as novel therapeutic agents. 2.(1) 4-(1-Arylsulfonylindol-2-yl)-4-hydroxycyclohexa-2,5-dien-1-ones and related agents as potent and selective antitumor agents.
    Berry JM; Bradshaw TD; Fichtner I; Ren R; Schwalbe CH; Wells G; Chew EH; Stevens MF; Westwell AD
    J Med Chem; 2005 Jan; 48(2):639-44. PubMed ID: 15658878
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery of inhibitors of the mitotic kinase TTK based on N-(3-(3-sulfamoylphenyl)-1H-indazol-5-yl)-acetamides and carboxamides.
    Laufer R; Ng G; Liu Y; Patel NK; Edwards LG; Lang Y; Li SW; Feher M; Awrey DE; Leung G; Beletskaya I; Plotnikova O; Mason JM; Hodgson R; Wei X; Mao G; Luo X; Huang P; Green E; Kiarash R; Lin DC; Harris-Brandts M; Ban F; Nadeem V; Mak TW; Pan GJ; Qiu W; Chirgadze NY; Pauls HW
    Bioorg Med Chem; 2014 Sep; 22(17):4968-97. PubMed ID: 25043312
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of Polo-like kinase 4 induces mitotic defects and DNA damage in diffuse large B-cell lymphoma.
    Zhao Y; Yang J; Liu J; Cai Y; Han Y; Hu S; Ren S; Zhou X; Wang X
    Cell Death Dis; 2021 Jun; 12(7):640. PubMed ID: 34162828
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery of novel allosteric mitogen-activated protein kinase kinase (MEK) 1,2 inhibitors possessing bidentate Ser212 interactions.
    Heald RA; Jackson P; Savy P; Jones M; Gancia E; Burton B; Newman R; Boggs J; Chan E; Chan J; Choo E; Merchant M; Rudewicz P; Ultsch M; Wiesmann C; Yue Q; Belvin M; Price S
    J Med Chem; 2012 May; 55(10):4594-604. PubMed ID: 22506516
    [TBL] [Abstract][Full Text] [Related]  

  • 13. YLT-11, a novel PLK4 inhibitor, inhibits human breast cancer growth via inducing maladjusted centriole duplication and mitotic defect.
    Lei Q; Xiong L; Xia Y; Feng Z; Gao T; Wei W; Song X; Ye T; Wang N; Peng C; Li Z; Liu Z; Yu L
    Cell Death Dis; 2018 Oct; 9(11):1066. PubMed ID: 30337519
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis and antitumor effect in vitro and in vivo of substituted 1,3-dihydroindole-2-ones.
    Christensen MK; Erichsen KD; Trojel-Hansen C; Tjørnelund J; Nielsen SJ; Frydenvang K; Johansen TN; Nielsen B; Sehested M; Jensen PB; Ikaunieks M; Zaichenko A; Loza E; Kalvinsh I; Björkling F
    J Med Chem; 2010 Oct; 53(19):7140-5. PubMed ID: 20845961
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A functional screening of the kinome identifies the Polo-like kinase 4 as a potential therapeutic target for malignant rhabdoid tumors, and possibly, other embryonal tumors of the brain.
    Sredni ST; Suzuki M; Yang JP; Topczewski J; Bailey AW; Gokirmak T; Gross JN; de Andrade A; Kondo A; Piper DR; Tomita T
    Pediatr Blood Cancer; 2017 Nov; 64(11):. PubMed ID: 28398638
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of novel aminoquinazolin-7-yl 6,7-dihydro-indol-4-ones as potent, selective inhibitors of heat shock protein 90.
    Huang KH; Barta TE; Rice JW; Smith ED; Ommen AJ; Ma W; Veal JM; Fadden RP; Barabasz AF; Foley BE; Hughes PF; Hanson GJ; Markworth CJ; Silinski M; Partridge JM; Steed PM; Hall SE
    Bioorg Med Chem Lett; 2012 Apr; 22(7):2550-4. PubMed ID: 22386527
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structure-based discovery of 1-(3-fluoro-5-(5-(3-(methylsulfonyl)phenyl)-1H-pyrazolo[3,4-b]pyridin-3-yl)phenyl)-3-(pyrimidin-5-yl)urea as a potent and selective nanomolar type-II PLK4 inhibitor.
    Sun Y; Wang L; Sun Y; Wang J; Xue Y; Wu T; Yin W; Qin Q; Sun Y; Wang H; Gao Y; Yang H; Zhao D; Cheng M
    Eur J Med Chem; 2022 Dec; 243():114714. PubMed ID: 36063666
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis and biological evaluation of 2-indolinone derivatives as potential antitumor agents.
    Zou H; Zhang L; Ouyang J; Giulianotti MA; Yu Y
    Eur J Med Chem; 2011 Dec; 46(12):5970-7. PubMed ID: 22019188
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 3-Aminopyrazole inhibitors of CDK2/cyclin A as antitumor agents. 2. Lead optimization.
    Pevarello P; Brasca MG; Orsini P; Traquandi G; Longo A; Nesi M; Orzi F; Piutti C; Sansonna P; Varasi M; Cameron A; Vulpetti A; Roletto F; Alzani R; Ciomei M; Albanese C; Pastori W; Marsiglio A; Pesenti E; Fiorentini F; Bischoff JR; Mercurio C
    J Med Chem; 2005 Apr; 48(8):2944-56. PubMed ID: 15828833
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activity of the novel polo-like kinase 4 inhibitor CFI-400945 in pancreatic cancer patient-derived xenografts.
    Lohse I; Mason J; Cao PM; Pintilie M; Bray M; Hedley DW
    Oncotarget; 2017 Jan; 8(2):3064-3071. PubMed ID: 27902970
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.